A Competing Risks Model with Binary Time Varying Covariates for Estimation of Breast Cancer Risks in BRCA1 Families

TL;DR

This paper develops a sophisticated statistical model to accurately estimate breast and ovarian cancer risks in BRCA1 families, accounting for time-varying factors, competing risks, and family selection biases, improving risk assessment precision.

Contribution

It introduces a new correlated competing risks model with flexible time-varying covariates and an ascertainment correction method for familial breast cancer risk estimation.

Findings

RRSO significantly reduces breast cancer risk in BRCA1 mutation carriers.

The model accurately estimates cause-specific penetrances and familial correlations.

Flexible covariate modeling improves risk assessment accuracy.

Abstract

Mammographic screening and prophylactic surgery such as risk-reducing salpingo oophorectomy (RRSO) can potentially reduce breast cancer risks among mutation carriers of BRCA families. The evaluation of these interventions is usually complicated by the fact that their effects on breast cancer may change over time and by the presence of competing risks. We introduce a correlated competing risks model to model breast and ovarian cancer risks within BRCA1 families that accounts for time-varying covariates (TVCs). Different parametric forms for these TVCs are proposed for more flexibility and a correlated gamma frailty model is specified to account for the correlated competing events. We also introduced a new ascertainment correction approach that accounts for the selection of families through probands affected with either breast or ovarian cancer, or unaffected. Our simulation studies demonstrate the good performances of our proposed approach in terms of bias and precision of the estimators of model parameters and cause-specific penetrances over different levels of familial correlations. We apply our new approach to 498 BRCA1 mutation carrier families recruited through the Breast Cancer Family Registry. Our results demonstrate the importance of the functional form of the TVC when assessing the role of RRSO on breast cancer. In particular, under the best fitting TVC model, the overall effect of RRSO on breast cancer risk was statistically significant in women with BRCA1.